-
公开(公告)号：US12163153B2
公开(公告)日：2024-12-10
申请号：US16857394
申请日：2020-04-24
Applicant: ALLOGENE THERAPEUTICS, INC.
IPC: C12N5/00 , A61K35/17 , C12N5/0783
Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).
-
公开(公告)号：US11781248B2
公开(公告)日：2023-10-10
申请号：US16900602
申请日：2020-06-12
Applicant: ALLOGENE THERAPEUTICS, INC.
Inventor： Thomas Charles Pertel , Barbra Johnson Sasu
CPC classification number: C40B40/10 , C07K16/40 , C12N15/63 , C07K2317/565
Abstract: The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
-
公开(公告)号：US11896617B2
公开(公告)日：2024-02-13
申请号：US16857573
申请日：2020-04-24
Applicant: ALLOGENE THERAPEUTICS, INC.
Inventor： Thomas Charles Pertel , Barbra Johnson Sasu , Mark W. Leonard
IPC: C12N15/62 , A61K35/17 , A61P35/00 , C07K14/705 , C07K16/28 , C12N5/0783 , A61K39/00
CPC classification number: A61K35/17 , A61P35/00 , C07K14/70517 , C07K14/70596 , C07K16/2803 , C12N5/0636 , A61K2039/505 , C07K2317/76 , C07K2319/33 , C12N2510/00 , C12N2740/15043
Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.
-
公开(公告)号：US11732041B2
公开(公告)日：2023-08-22
申请号：US16851691
申请日：2020-04-17
Applicant: ALLOGENE THERAPEUTICS, INC.
Inventor： Thomas Charles Pertel , Barbra Johnson Sasu , Tao Sai
CPC classification number: C07K16/2803 , A61K35/17 , C07K16/4241 , C07K2317/565 , C07K2317/622 , C07K2317/92
Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.
-
公开(公告)号：US20220033462A1
公开(公告)日：2022-02-03
申请号：US17385805
申请日：2021-07-26
Applicant: ALLOGENE THERAPEUTICS, INC. , CELLECTIS
Inventor： ARVIND RAJPAL , Shobha Chowdary Potluri , Laurent Poirot , Alexandre Juillerat , Thomas Charles Pertel , Donna Marie Stone , Barbra Johnson Sasu
IPC: C07K14/705 , C07K16/30 , A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783
Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.
-
Patent Agency Ranking
公开(公告)号：US11786553B2
公开(公告)日：2023-10-17
申请号：US16804545
申请日：2020-02-28
Applicant: Allogene Therapeutics, Inc.
Inventor： Regina Junhui Lin , Thomas John Van Blarcom , Siler Panowski , Barbra Johnson Sasu
CPC classification number: A61K35/17 , C07K14/7155 , C07K16/2818 , C07K16/30 , C12N15/67 , A61K38/00 , C07K2319/03 , C07K2319/33 , C07K2319/74
Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.
-
公开(公告)号：US12215347B2
公开(公告)日：2025-02-04
申请号：US17381693
申请日：2021-07-21
Applicant: Allogene Therapeutics, Inc.
Inventor： Michael Thomas Bethune , Yi Zhang , Thomas John Van Blarcom , Siler Panowski , Barbra Johnson Sasu
IPC: C12N5/0783 , A61K39/00 , C07K14/725 , C12N15/86
Abstract: Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.
-
公开(公告)号：US12036243B2
公开(公告)日：2024-07-16
申请号：US17183689
申请日：2021-02-24
Applicant: Allogene Therapeutics, Inc.
Inventor： Regina Junhui Lin , Siler Panowski , Cesar Adolfo Sommer , Thomas John Van Blarcom , Barbra Johnson Sasu , Arun Balakumaran
IPC: A61K35/17 , A61P35/00 , C07K14/715 , C07K16/28 , C12N15/86
CPC classification number: A61K35/17 , A61P35/00 , C07K14/7151 , C07K16/2878 , C12N15/86
Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.
-
公开(公告)号：US11673953B2
公开(公告)日：2023-06-13
申请号：US16802822
申请日：2020-02-27
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Yi Zhang , Thomas John Van Blarcom , Siler Panowski , Silvia K. Tacheva-Grigorova , Barbra Johnson Sasu
CPC classification number: C07K16/2809 , A61P35/00 , C07K16/2887 , C12N15/63 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2319/70
Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
-
公开(公告)号：US12043655B2
公开(公告)日：2024-07-23
申请号：US16804917
申请日：2020-02-28
Applicant: Allogene Therapeutics, Inc.
Inventor： Regina Junhui Lin , Thomas John Van Blarcom , Siler Panowski , Barbra Johnson Sasu
IPC: C07K14/715 , A61K35/17 , A61K39/00 , A61P35/00 , C07K16/40 , C12N5/0783 , C12N7/00 , C12N15/86
CPC classification number: C07K14/715 , A61K35/17 , A61P35/00 , C07K16/40 , C12N5/0636 , C12N7/00 , C12N15/86 , C07K2317/24 , C07K2317/73 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C12N2740/15043
Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.016 seconds)
